Noble Capital Markets has announced that Rob Goldman will be a featured Metaverse panelist at NobleCon18, which feature presentations from 120 public companies on April 20 and 21 at The Guitar Hotel near Miami, FL. Joining Facebook (NASDAQ: FB) in 2012 reporting directly to CEO Mark Zuckerberg, Goldman was charged with growing and monetizing the burgeoning social media platforms (including subsidiaries such as Instagram). During his tenure at Facebook, revenues grew from $5 billion to over $70 billion in a span of seven years. Goldman’s move to Facebook happened when his company, Threadsy, was acquired by the social media giant in a move that many refer to as one of “Mark Zuckerberg’s acqui-hires.” Goldman’s company started out as a way for people to see their social feeds and communication from different networks, like Facebook and Twitter, in one place. But Goldman soon changed the focus towards a paid service that helped brands see which influencers they needed to establish relationships with in order to find new customers on social networks. The change resulted in the development of the social marketing tool Swaylo, which ultimately attracted the attention of Zuckerberg. Mr. Goldman is a graduate of Harvard Business School. Admission to NobleCon is free for all levels of investors from self-directed novices to institutional investors, thanks to Noble, Channelchek, Sponsors and The Presenting Companies. Attendance is limited to 1,000. To secure a ticket, visit https://nobleconference.com/register/investor-guest Full list of speakers: https://channelchek.com/news-channel/Scheduled_Speakers_NobleCon18 The presenting companies: https://channelchek.com/news-channel/NobleCon18_Presenting_Companies

• RWB’s mission has always been to become the superior and most recognizable cannabis company in the United States
• It seeks to achieve this by focusing on the continued growth of top-line revenue and bottom-line results through brand expansion, mergers, and acquisitions
• So far, in 2022, the company has announced the acquisition of PharmaCo, which sees the transfer of 21 medical and adult-use cannabis licenses
• RWB has also closed a lease assignment on a critical manufacturing/processing and distribution facility in Michigan
• Its management is confident that the foundations laid down so far will aid in the company’s growth going forward

In 2020, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) set out on a three-year plan for success. The initial strategy was to form a solid foundation to define its identity while cementing its position in crucial states within the United States. So far, the company has set base in Michigan, Florida, California, and Illinois, in what marks an aggressive and successful expansion plan. “For the balance of 2021 and throughout 2022, the company will focus on the continued growth of our top-line revenue and bottom-line results through expansion of our house of brands that continue to gain momentum, fortification of our vertically integrated businesses, and the synergies from our M&A success,” noted Brad Rogers, the Chairman and Chief Executive Officer (“CEO”) of the company (https://ibn.fm/b9Tf0). In line with these goals and projections, RWB announced the acquisition of PharmaCo, in a transaction initially announced back on July 27, 2020. The purchase sees the transfer of 21 medical and adult-use cannabis licenses to RWB. Additionally, the company now has access to eight fully-operating dispensaries, two operational indoor cultivation facilities, one municipality licensed 10-acre outdoor cultivation facilities, and 22 owned properties for potential additional cultivation and dispensary locations, among others (https://ibn.fm/crX2V). “I’m pleased to announce that we have closed on the PharmaCo acquisition and now control all aspects of our Michigan operations,” noted Mr. Rogers. “This is a major milestone for RWB and its shareholders as we continue to execute key components of our growth strategy and build our house of brands across our core markets, as promised. We are now in the driver’s seat on over 20 assets across Michigan- one of the largest and fastest-growing cannabis markets in the country,” he added. At the beginning of the 2022 calendar year, RWB also closed on a lease assignment for a 15,000 square foot manufacturing/processing and distribution facility in Warren, Michigan. The property already has both medical and adult-use licenses, which allow RWB to begin manufacturing medical and adult-use cannabis products while leveraging a centralized distribution that the existing infrastructure provides (https://ibn.fm/OL1ly). This move also saw RWB’s expansion of its Platinum Vape products and the strengthening of its human resources following the hiring of 30 full-time employees with the objective of growing the number to 50 over the course of the year. Additionally, at the close of the 2021 calendar year, RWB settled a CAD$5.1 million debt and refinanced a CAD$12.8 million acreage Florida acquisition note. It also announced a $6 million year-over-year increase in revenue for the third quarter of the 2021 financial year, representing a 93% growth. In a statement from Mr. Rogers, he noted: “In the third quarter, we made excellent progress in laying additional building blocks in our core operating states of Florida, Michigan, and California to become more vertically integrated where it will be most profitable” (https://ibn.fm/YAyla). The company remains optimistic that the upward trajectory in growth and performance will carry on throughout the 2022 calendar year. The foundations laid down so far line up with the company’s goals and objectives as it gains momentum and fortifies its vertically integrated businesses. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations
• CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiforme
• Interim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients have been on the study for six months

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system, has released a video to its shareholders that reiterates the operational and clinical progress of its lead drug candidate, Berubicin. The video features CNS CEO John Climaco and addresses the recent share price activity (https://ibn.fm/Z40Gw). “The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market – both of which are things out of our control,” Climaco said in his video message. “However, as the CEO, what I do have control over is executing on the day-to-day operations, which I want to reiterate and emphasize have simply never been stronger.” Climaco went on to detail the company’s operational strengths, including the fact that it continues to enroll patients in its potentially pivotal global study of Berubicin in the treatment of adult glioblastoma multiforme (“GBM”). “We have the leading minds in the field around the world working on this trial with us, and we have encouraging ongoing dialogue with the FDA to ensure that our potentially pivotal trial continues to represent the state-of-the-art in the field,” he said. The CNS CEO also underlined that his company remains committed to continuing to execute its operational excellence to drive recognition in the market of Berubicin and its immense potential for patients – the key driver for ultimately generating shareholder value and tremendous hope for GBM patients worldwide. “We put our heads down every day and continue to charge forward in our mission to change the game in glioblastoma via Berubicin,” Climaco added. The video comes days after the company released its full-year 2021 financial results and corporate update, highlighting key milestones during the previous year, including (https://ibn.fm/Lb1r3):

• May 2021 – Beginning of patient enrollment for a potentially pivotal global study evaluating the efficacy of Berubicin for adult recurring GBM
• June 2021 – Granting of Fast Track Designation by the FDA for recurrent GBM treatment with Berubicin
• September 2021 – First patients from potentially pivotal study dosed with Berubicin
• December 2021 – Approval from “swissethics,” the umbrella organization of the Ethics Committee (“EC”) in Switzerland, for the potentially pivotal study of Berubicin for treatment of recurrent GBM to proceed in Switzerland
• January 2022 – Announcement of $11.5 million private placement, priced at the market under NASDAQ rules

CNS plans to expand the potentially pivotal study of Berubicin in recurrent GBM into additional countries and complete the enrollment needed for the interim analysis of the study within the year. The interim analysis of the trial will occur when 30-50% of the total expected patients have been on the study for at least six months, which is anticipated during the first half of 2023. Berubicin is a novel anthracycline and the first that appears to cross the blood-brain barrier. It is currently in development for the treatment of a number of serious brain and oncology indications. The first trial of the drug was initiated by Reata Pharmaceuticals over 16 years ago. It resulted in one patient surviving cancer-free, and two others reporting a reduction in tumor size of up to 80%. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Cannabis sales in Colorado broke another record last year, topping $2.22 billion in products sold
• Cannabis is “massive” driver of tax revenue for Colorado, raking in over $423 million last year alone
• HENC continues to pursue diversification and integration strategy through subsidiary

Another record-breaking year for Colorado’s cannabis industry bodes well for Hero Technologies (OTC: HENC). The company anticipates expanding into the booming market via cultivation and dispensary operations through its wholly owned subsidiary, Mile High Green LLC. Cannabis sales in the state broke another record last year, topping $2.22 billion in products sold, according to the Colorado Department of Revenue (https://ibn.fm/NNChl). This figure “eclipses” 2020 sales reaching upwards of $2.1 billion, which set a previous record, reported a recent “CPR News” article (https://ibn.fm/uSmIo). “Peter Marcus, a spokesperson for the recreational and medical cannabis dispensary chain Terrapin Care Station, wasn’t surprised when he saw the latest numbers from the state,” the article noted. “Popularity for cannabis has only grown since the state-licensed retail sales of the plant in 2014, he said. Plus, 2021, just like its predecessor, was filled with pandemic anxiety.” The article quoted Marcus, who stated, “We find during crises times that people tend to turn to relief, and previously it had been alcohol. I think having this legal alternative was a significant shift for people. What we learned from the pandemic is that cannabis is more or less recession-proof.” According to “CPR News,” cannabis sold by both medical and retail cannabis stores has totaled more than $12.2 billion since the state began tracking cannabis sales in January 2014. “Retail cannabis made up the vast majority of last year’s sales, approximately 82% or $1.82 billion of the $2.22 billion,” the article noted. “Business peaked in March 2021 when retailers brought in more than $207 million that month. “Cannabis is a massive driver of tax revenue for Colorado, raking in over $423 million last year alone and upwards of $2 billion since 2014 in sales and excise taxes and fees,” the CPR article continued. “It’s also a big employer. According to an annual Leafly report, over 35,500 Coloradans worked in the cannabis industry in 2021.” Hero Technologies announced the formation of Mile High Green in March of last year, stating that the purpose of the subsidiary was to seek cannabis license, land purchase and strategic acquisition opportunities in the state of Colorado (https://ibn.fm/DeXf4). “By establishing another subsidiary to target cannabis property acquisitions and cannabis licenses, we continue to aggressively pursue our diversification and integration strategy,” said Hero Technologies CEO Gina Serkasevich. “Colorado is an obvious market for us to target for expansion. It was exciting to see the state’s cannabis sales soar to $2.2 billion in 2020, truly an all-time high. We will work hard to gain market share in this important territory and participate in its healthy growth.” Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Company SEC filing outlines company mission, unique differentiation
• Company uses ML, NL processing to comprehend huge amounts of data thousands of times faster than humans with significantly reduced errors, more objectivity
• Pluaris is a subscription-based SaaS product platform that adapts to user needs

Almost a decade ago, Nowigence Inc. (NOWG) started on its mission to create an artificial intelligence software platform that could read and comprehend data. Today, the company is proud to offer Pluaris, a cloud-based app that automates reading and analysis of textual data so users can learn more in less time, uncover hidden insights and stay on top of the information they need to know. Nowigence’s focus has expanded since those formative early years. Its filing with the Securities Exchange Commission (“SEC”) states that Nowigence is committed to create an AI platform to rapidly read and comprehend data using machines, whether unstructured or structured, in the data’s right context and provide business professionals with a toolkit to anticipate their future through data, predict scenarios, and keep plan-ready, united and confident to meet their business goals (https://ibn.fm/1EGYc). “Any technology-based solution is successful if it increases speed while reducing error,” the filing continues. “In our case, we use machine learning and natural language processing to comprehend huge amounts of data in real time many thousands of times faster than human abilities with significantly reduced errors and larger objectivity.” Pluaris is built around a unique differentiation. “Our view of the market is that AI using ML/NLP techniques is currently a project-based service industry,” the company states. “Clients hire coding engineers, data scientists and project managers to scope the requirements of a specific use case in the form of technical specs, which is then converted into a solution. This consultancy-based approach is not scalable. From a customer’s perspective, it is expensive, time consuming and does not guarantee success.” Seeking to provide a scalable alternative, Nowigence created Pluaris, a subscription-based SaaS product platform that adapts to the needs of its users. Designed to work across different functions and sectors, Pluaris is easy to learn, allowing users to customize, work with and benefit from the product from day one. Another unique aspect of Nowigence’s unique offering is that Pluaris is one of only a few solutions that allow users direct access to the database. “Most other cognitive information retrieval engines allow access from an intermediate interface where human-controlled quality screening has already ascertained the accuracy of the results,” the company observes. “Operating directly from the database provides two main benefits for users. The first is that the output is in real time or near real time, depending upon the frequency at which the data is refreshed. The second is that data anomalies are detected faster and are corrected in the database to prevent propagation of erroneous data. Our algorithms allow users to get to quality outputs faster than other competitive service offerings.” Nowigence is committed to helping individuals, teams and enterprises quickly distill knowledge from massive amounts of textual data, both public and private. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

The Bitcoin Miami Kickoff Party taking place on Monday, April 4th, is the kickoff event for the reBLOCKmiami conference being held Tuesday, April 5th, at the Hilton Miami Airport Blue Lagoon, and is the perfect pre-conference kickoff atmosphere for making critical initial contacts while having a great time, especially if you are an entrepreneur, attorney, CPA, or investor in the Crypto, NFT, or De-Fi industry. The reBLOCKmiami conference focuses on the Real Estate Blockchain space, and the kickoff party is for anyone that wants to connect prior to the formal conference, on a fun and personal basis, with the movers and shakers in this sector. Industry insiders will be making deals and valuable connections. In fact, we ensure success by having ambassadors actively connecting you around. Everyone knows that connections made in a more personal environment are the most meaningful. A positive and fun setting allows communication at another level, building relationships and friendships that can last for years, in addition to providing a flow of rich information that can give you the inside track on what’s really happening. Some of the biggest and best deals can result from the most enjoyable and informal environments, so don’t miss out. The party event is being held at the popular Biscayne Bay Brewing Company in Miami, offering an atmosphere that includes great craft beers and appetizers. In addition, we’ve landed world-renowned DJ Wildstyle to ensure it all keeps going.  For individual passes visit https://ibn.fm/l3fze. For group discounts, email Andrew@FloridaBlockchainSummit.com.  For additional kickoff event information, visit https://ibn.fm/zdFwv.

• Easing federal regulations on cannabis will benefit cannabis companies
• Republican congresswoman says she has received assurances that her proposed cannabis bill will receive a hearing
• ACP operates in two states where cannabis is legal and is exploring expansion opportunities in additional states

Despite the House and Senate being controlled by the Democrats, Nancy Mace, a Republican representative from South Carolina, has said her proposed cannabis bill will get a hearing (https://ibn.fm/VWivR). Easing federal regulations on the substance, which Mace’s bill is designed to do, will benefit cannabis companies, including American Cannabis Partners (“ACP”), that are currently operating in states with legalized medical and recreational cannabis use. “As advocates push for congressional action on Democratic-led marijuana legalization bills in the House and Senate, a Republican congresswoman who’s championing an alternative reform measure says she has received assurances that there will be a hearing on her proposal even as a minority member of the chamber,” reported a “Marijuana Moment” article released earlier this month. “She also said that recent internal polling she’s done for her reelection campaign shows voters in her district are on her side when it comes to cannabis even as her primary election challenger and her own state party attack her reform efforts.” In the article, the status and anticipated progress of Mace’s States Reform Act (“SRA”) was discussed. “There was earlier reporting about Mace receiving assurances that Democratic leaders would hold a hearing on her bill,” the article stated. “But when asked whether that was contingent on a yes vote for a separate legalization bill—House Judiciary Committee Chairman Jerrold Nadler’s (D-NY) Marijuana Opportunity, Expungement and Reinvestment (‘MORE’) Act—the congresswoman said there was ‘no quid pro quo.’ “‘Personally, I want to respect the process, and MORE is going to come up again and let Democrats do the MORE Act. It’ll die in the Senate,’ she said. ‘And so when that’s done, we will do our hearing, and there was nothing done in exchange for it. I just made the ask, and we’re making it happen,’” the article quoted. “The congresswoman didn’t say when exactly she expects the hearing on her proposal, but it appears she expects it to happen sometime after a possible House floor vote on the MORE Act. Drug policy and civil rights groups sent a letter this week urging House leaders to schedule that vote to happen sometime this month.” The activity on the hill, while slow, appears to be movement in the right direction. Currently the use, sale and possession of cannabis with more than 0.3% THC is prohibited under the federal Controlled Substances Act of 1970, although a majority of states have taken the legalization of cannabis into their own hands. Currently cannabis use is legal for adults in 18 states and Washington, DC, with medical marijuana being legal in 38 states and DC (https://ibn.fm/7Ey0e). Cannabis companies around the country are watching this momentum closely, including American Cannabis Partners, which operates in Michigan and California. ACP is also in the process of exploring land acquisition and project development strategies for expanding operations to additional states. The company is focused on three business segments: real estate, acquisition and development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with more than three decades of canna-business experience, ACP is guided by its strategy to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on federal interstate commerce opportunities. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints
• In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous system
• The company signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD
• Silo currently has under review four U.S. patent applications related to psilocybin treatment of cancer and central nervous system delivery of therapeutics
• The company has engaged Donohoe Advisory to explore uplisting Silo’s shares on the Nasdaq

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry. Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space. Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves. Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market. Research Silo has entered into research agreements and partnerships with multiple leading medical universities. The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee. Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (“UCSF”). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (“TrPR”) Program at UCSF. Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (“UMB”) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents. This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future. Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data. In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod(TM) technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.” Market Overview According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress. The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics. Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine. Management Team Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business. Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine. Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training. Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• Eat Well Investment Group Inc. is a rapid-growth supplier of nutritious, plant-based food products for people and pets
• Amid large disruptions to global food security occasioned by the COVID-19 pandemic and war in Ukraine, Eat Well is working to overcome supply chain obstacles to further its mission of supplying the world with nutritious, life-enhancing food
• The company formed last year but its leadership has a broad depth of experience and its three major acquisitions sold over 26,000 tons of pure plant-based protein to over 35 countries worldwide during the first year of the pandemic
• In a March 8 shareholder update letter, CEO Marc Aneed said 2021 financials are forthcoming and are expected to confirm forecasts of about $60 million in revenues with bottom-line profitability and continued growth for 2022
• Statista analysts predict the plant-based foods market will more than double by 2030 from expected revenue generation of $44.2 billion this year

The Russia-Ukraine war is raising warning flags about global food security that was already stressed by the ongoing COVID-19 pandemic and other factors that preceded it. Russia is the world’s largest exporter of wheat and Ukraine is the world’s fifth-largest, and the conflict in the world’s breadbasket has disrupted almost a third of the world’s wheat market, according to data reporting by Sky News (https://ibn.fm/lOI0X). Vertically integrated plant-based foods company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) is a new and growing company strengthening its end-to-end supply chain production of nutritious foods through strategic acquisitions, working to overcome global forces such as the war in Ukraine in its efforts to transform entire industries such as meat and dairy with nutrition-focused operations. “The world is witnessing one of the worst global supply chains in history. Getting products in containers on planes, trains, and ships to meet the demand remains a formidable task; however, I have the utmost confidence in our teams and partners. … We continue to deploy the utmost of business pragmatism and creative thinking to overcome supply chain disruptions presented by Covid-19, weather, and now the Russia-Ukraine conflict,” CEO and Director Marc Aneed told shareholders in a business update letter published March 8 (https://ibn.fm/pHvJs). “Though we are only eight months old, we’ve been 40 years in the making with a deep repertoire and history of winning,” Aneed continued. “Our investments are deeply rooted in North America, with Canada as the heart of the worldwide pulse sector for plant-based proteins, so we continue to be well-positioned to keep feeding the world with high-quality, highly nutritious plant-based foods.” His Royal Highness Prince Khaled bin Alwaleed bin Talal Al Saud of Saudi Arabia, a pioneer in plant-based food investing who joined Eat Well Investment Group as an advisor last year, noted that during the initial year of the COVID pandemic Eat Well’s portfolio companies sold over 26,000 tons of pure plant-based protein to over 35 countries worldwide, not only helping to sustain improvements in nutrition and strengthen food security but also providing noteworthy benefits to the environment through methane reduction (https://ibn.fm/Hx1tV). “We believe food plays a central role in all human societies and is a key determinant of our overall well-being. Food and agricultural infrastructure are the cornerstones of all cultures, and we want to celebrate and grow Canada’s rich heritage and capabilities to feed people on a global scale,” the company’s mission statement adds (https://ibn.fm/YXpgL). More than 35 percent of the world’s supply of pulse proteins originates in Canada and the plant-based foods market is expected to more than double by 2030, according to analysts at Statista, who reported the emerging sector should deliver revenues of $44.2 billion this year and $77.8 billion in 2025 prior to the escalation of the Ukraine war (https://ibn.fm/rsVOF). In 2021, Eat Well acquired plant-based ingredients processor Belle Pulses, plant-based food creator Sapientia and affordable baby and children’s food company Amara, plus added an OTC listing in the United States to its Canadian Stock Exchange trades. “While we successfully executed three major investments within a short time in 2021, we will be making further selective investments to expand each of our portfolio companies’ business reach and adding team members to bolster our functional experience in critical areas,” Aneed stated in the shareholder update. “While our 2021 year-end financials will be out shortly, we maintain our guidance in the forecasted range for our investments at [about] $60MM with bottom-line profitability. The 2022 ambition remains to generate $90-$110MM and, with gross margins that will stand the test of time as the teams drive growth in their respective sectors.” For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• FeaturedX Co-founders Ryan “Tuck” O’Leary and Jeff Menig will stay on in their roles
• Robert A. Rositano Jr., CEO of Friendable, marks the acquisition and retention of the co-founders to be a step forward in the pursuit of offering the ultimate 360 artist offering – focusing on revenue, artists, and additional services
• In 2022, Friendable has seen remarkable growth for its Fan Pass Live platform, with over 111,000 artists now available and social media trending upward

Friendable (OTC: FDBL), a mobile technology and marketing company, has announced the initial launch and release of FeaturedX.com – a web-property acquired in January 2022. FeaturedX currently has thousands of artists available and is a platform where artists can tap into resources for music production and collaboration, including booking a guest feature, co-writing, MIDI composition, and more. Also announced with the launch was the retention of the original co-founders, Mr. Ryan “Tuck” O’Leary and Mr. Jeff Menig (https://ibn.fm/qh6nG). Robert A. Rositano Jr., CEO of Friendable, commented on the announcement, saying that while continuing to deliver a variety of expanded services to artists, platforms, and offerings, FeaturedX has taken center stage as Friendable’s next service offering ready for growth. “Working closely with Mr. O’Leary and Mr. Menig, the two original co-founders of FeaturedX, it was immediately clear that having them both on board for our journey forward would be one of our keys to success. This said, we have been able to reach an agreement with both O’Leary and Menig to join our team as partners as we focus on revenue, artists, and additional services growth on a platform that already has great momentum,” Rositano Jr added. Lifelong friends O’Leary and Menig launched FeaturedX in 2020. O’Leary is best known for playing bass in the “Texas Metal” band Fit for a King. Menig has over 21 years of professional entertainment industry experience working with band management, live events, merchandise, consulting, artist development, and marketing. Menig’s experience and a keen eye for detail will make him invaluable to the team as Fan Pass Live grows the FeaturedX brand and services. “Creating this lineup was an absolute dream of mine. This is a dream team of the greatest artists in alternative music,” O’Leary said. “Combining years of friendships and touring experience, we built this as a community. Now teaming up with Fan Pass Live, FeaturedX is looking to continue expanding and growing an already stellar roster of creatives,” he added. In the acquisition, Friendable positioned itself as the first 360 artist platform to provide artists with a start to finish solution for independent music distribution through its flagship offering, Fan Pass Live artist platform, and the newly acquired Artist Republik and FeaturedX. Friendable’s mission is to provide the ultimate “anti-label” experience, keeping artists in control of their music. The total artist offering now being offered by Friendable through Fan Pass Live, Artist Republik, and FeaturedX include:

• Music production
• Music collaboration
• Music distribution services
• Promotion
• Live events
• Ticket sales
• Behind the scenes
• Merchandise design/shop
• Tips
• Fan interaction opportunities
• Subscription offerings
• And so much more

Through the different avenues, artists can earn revenue – either through the sales of subscription services or through ticket sales and tips to music streams and merchandise. This year, Friendable has seen remarkable growth in its social media numbers, and engagement is rising. With a catalog of over 111,000 artists, fans can experience indie artists like never before without paying the prices required by a label. The Fan Pass Live platform makes connecting fans with artists much easier and allows for a more personal connection at every point in the music ecosystem. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL